Obstructive Sleep Apnea
Conditions
Keywords
Postprandial glucose, lipid metabolism, humoral factors
Brief summary
The purpose of this study is to examine postprandial glucose and lipid metabolism in patients with obstructive sleep apnea.
Detailed description
Obstructive sleep apnea (OSA) is an increasingly prevalent condition that is characterized by repetitive upper airway obstructions. OSA has been independently associated with insulin resistance, suggesting that OSA may contribute to the development of type 2 diabetes and the metabolic syndrome. Recently, postprandial glucose and lipid have been reported as excellent predictors for mortality and cardiovascular risk. However, the association between postprandial glucose, lipid metabolism and OSA are not clear. In addition, humoral factors such as ghrelin and leptin are associated with obesity and OSA, but postprandial changes of which in patients with OSA are not well known. The aim of present study is to examine postprandial glucose and lipid metabolism, humoral factors in OSA before and after 3 months of continuous positive airway pressure (CPAP) treatment.
Interventions
DEVICECPAP treatment
maintains upper airway patency and minimizes the obstructive events
Sponsors
Kyoto University, Graduate School of Medicine
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects on admission for sleep study under the Respiratory Care and Sleep Control Medicine, Kyoto University Hospital. * Subjects diagnosed with OSA (apnea hypopnea index \>=5/hour) by overnight polysomnography.
Exclusion criteria
* Subjects treating for acute infections or malignancy. * Subjects with severe anemia, diabetes,and renal failure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| postprandial metabolic markers including glucose, cholesterol, triglyceride, ghrelin, leptin | baseline and 3 months after CPAP |
Secondary
| Measure | Time frame |
|---|---|
| inflammatory biomarkers (ie. IL-6, CRP) | baseline and 3 months after CPAP |
| quality of life | baseline and 3 months after CPAP |
| sleep quality | baseline and 3 months after CPAP |
| respiratory events (ie. apnea-hypopnea index) | baseline and 3 months after CPAP |
| appetite | baseline and 3 months after CPAP |
| endothelial function | baseline and 3months after CPAP |
| sympathetic activity in urine | baseline and 3 months after CPAP |
Countries
Japan
Outcome results
None listed